On October 13th, the innovative Class 1 anti-influenza drug Jikeshu (Sebaloxavir Marboxil Tablets), which only requires one dose of medication for the entire course of treatment, was launched online on the JD Health platform. JumpCan Pharmaceutical relies on JD Health's advantage of being the first stop for the launch of new special drugs on the entire network, further promoting the accessibility and convenience of Jikeshu in anti-influenza treatment, and providing new treatment options for more influenza patients.

 

 

Jikeshu is a new generation of targeted influenza virus RNA polymerase PA inhibitor independently developed by China with global independent intellectual property rights. In 2023, JumpCan Pharmaceutical and Zenshine Pharmaceutical reached a strategic cooperation around Jikeshu. The company enjoys the exclusive promotion and sales rights of Jikeshu in mainland China. In July this year, it was approved by the National Medical Products Administration (NMPA) for listing.

 

Clinical studies have shown that Jikeshu has a long half-life, high plasma exposure levels, and supports one-time use throughout the entire course of treatment. There is no need to adjust the dosage based on body weight, making medication more convenient and providing long-lasting care for health; After taking Jikeshu, the peak blood drug concentration can be reached within 3 hours, with rapid onset of action, fever reduction within 1 day, significant improvement in all influenza symptoms within 39.4 hours, rapid clearance of influenza virus, and shortened course of illness; The incidence of adverse events related to Jikeshu is low, and there are few drug interactions through non-CYP enzyme metabolic pathways. In addition, the clinical research subjects of Jikeshu are all Chinese patients, and the clinical medication is more targeted and applicable, in line with the physiological characteristics of the Chinese population, providing a " single-dose, full-course" Chinese treatment plan for fighting against influenza.

 

With the normalization of the flu season, efficient, safe, and convenient treatment options have become a common demand for clinical practice and patients. Jikeshu adopts a "single oral, fully effective" dosing regimen, which is expected to bring a "long-lasting, one-day fever reduction, and safe use" medication experience to influenza patients.

 

The online launch of Jikeshu in the cooperation between JumpCan Pharmaceutical and JD Health is not only based on a high level of trust in JD Health's professional drug supply chain and precise user outreach capabilities, but also a strong alliance between the two parties to accelerate the popularization of innovative drugs to the people. It will enhance the experience of pharmaceutical consumers with richer and higher quality product supply, faster delivery time, and better service guarantee.

 

 

In the future, JumpCan Pharmaceutical will take "Build a joyful and vibrant life together" as its vision, adhere to a patient-centered approach, accelerate the layout of advantageous disease fields, provide high-quality products, upgrade to new retail and digital transformation, drive brand momentum, create new quality growth, continue to fulfill the social responsibility of listed pharmaceutical companies, and safeguard public health.